Avience Biomedicals Ltd
- Market Cap ₹ 114 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 22.6
- Book Value ₹
- Dividend Yield %
- ROCE 31.6 %
- ROE 38.2 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 36.0%
Cons
- Debtor days have increased from 75.0 to 113 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 10.15 | 10.92 | 16.13 | 28.63 | |
| 8.93 | 9.49 | 12.88 | 20.95 | |
| Operating Profit | 1.22 | 1.43 | 3.25 | 7.68 |
| OPM % | 12.02% | 13.10% | 20.15% | 26.83% |
| 0.00 | 0.01 | 0.38 | 0.57 | |
| Interest | 0.16 | 0.27 | 0.44 | 0.64 |
| Depreciation | 0.09 | 0.20 | 0.44 | 0.75 |
| Profit before tax | 0.97 | 0.97 | 2.75 | 6.86 |
| Tax % | 24.74% | 18.56% | 26.91% | 27.11% |
| 0.72 | 0.78 | 2.00 | 5.00 | |
| EPS in Rs | 3.54 | 2.37 | 6.09 | 15.22 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 41% |
| TTM: | 78% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 91% |
| TTM: | 153% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 36% |
| Last Year: | 38% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 2.03 | 3.28 | 3.28 | 4.03 |
| Reserves | 0.76 | 0.79 | 2.78 | 16.37 |
| 2.49 | 2.66 | 7.73 | 13.74 | |
| 0.82 | 3.29 | 11.82 | 9.42 | |
| Total Liabilities | 6.10 | 10.02 | 25.61 | 43.56 |
| 1.17 | 2.52 | 6.80 | 8.82 | |
| CWIP | 0.00 | 0.00 | 0.03 | 4.62 |
| Investments | 0.00 | 0.00 | 5.73 | 5.73 |
| 4.93 | 7.50 | 13.05 | 24.39 | |
| Total Assets | 6.10 | 10.02 | 25.61 | 43.56 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Net Cash Flow | ||||
| Free Cash Flow | ||||
| CFO/OP |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 90.98 | 56.82 | 54.76 | 113.34 |
| Inventory Days | 71.44 | 166.08 | 269.38 | 172.84 |
| Days Payable | 11.18 | 59.58 | 143.60 | 106.17 |
| Cash Conversion Cycle | 151.25 | 163.32 | 180.54 | 180.01 |
| Working Capital Days | 52.14 | 25.07 | -140.30 | 22.69 |
| ROCE % | 20.65% | 30.99% | 31.59% |
Documents
Annual reports
No data available.